Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer

por Clark, Curtis A., Yang, Eddy S.
Publicado 2021

Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors

por Clark, Curtis A., Yang, Eddy S.
Publicado 2022

Efficacy of c-Met inhibitor for advanced prostate cancer

por Tu, William H, Zhu, Chunfang, Clark, Curtis, Christensen, James G, Sun, Zijie
Publicado 2010

Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Media...

por Moradi, Luke A., Clark, Curtis A., Schneider, Craig S., Deshane, Alok S., Dobelbower, Michael C.
Publicado 2021

CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

por Reyes, Ryan M, Zhang, Chenghao, Deng, Yilun, Ji, Niannian, Mukherjee, Neelam, Padron, Alvaro S, Clark, Curtis A, Svatek, Robert S, Curiel, Tyler J
Publicado 2021

Estrogen receptor beta signaling in CD8(+) T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch

por Yuan, Bin, Clark, Curtis A, Wu, Bogang, Yang, Jing, Drerup, Justin M, Li, Tianbao, Jin, Victor X, Hu, Yanfen, Curiel, Tyler J, Li, Rong
Publicado 2021

Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer

por Gupta, Harshita B, Clark, Curtis A, Yuan, Bin, Sareddy, Gangadhara, Pandeswara, Srilakshmi, Padron, Alvaro S, Hurez, Vincent, Conejo-Garcia, José, Vadlamudi, Ratna, Li, Rong, Curiel, Tyler J
Publicado 2016